Peptide LibraryVK2735 dosage in published studies and labels
These are the doses used for VK2735 in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
VK2735 has no approved dosage. Published human dosing comes from the phase 2 VENTURE trial, which gave once-weekly injections under the skin from 2.5 mg to 15 mg for 13 weeks to adults with obesity or overweight without diabetes; mean weight loss ranged from 9.1% to 14.7% against 1.7% with placebo. Phase 3 trials of 7.5, 12.5 and 17.5 mg weekly are under way, and an oral daily form has been tested in phase 2.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 2.5–15 mg once weekly in the phase 2 trial; 7.5–17.5 mg weekly in ongoing phase 3 |
| Route | Subcutaneous · Oral (separate daily tablet form, phase 2) |
| Frequency | Once weekly (injection); once daily (oral form) |
| Duration studied | 13 weeks in the published phase 2 trial |
| Titration | The VENTURE abstract reports titration to steady state; the step schedule is not given in the indexed abstract. |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| VENTURE — phase 2, weekly injection (NCT06068946)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 dose-ranging trial | Adults with obesity, or overweight with a weight-related condition, without diabetes (174 in the reported groups) | 2.5 mg to 15 mg (four dose groups) | Subcutaneous | Once weekly | 13 weeks | Mean weight loss from 9.1% (2.5 mg) to 14.7% (15 mg) against 1.7% with placebo; mostly gastrointestinal side effects | Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity (Silver Spring). 2026. |
| VANQUISH — phase 3, weight management (NCT07104500)Clinical trial · Phase 3 randomized, placebo-controlled trial, active not recruiting | Adults with obesity or overweight (n=4,500 planned) | 7.5, 12.5 or 17.5 mg | Subcutaneous | Once weekly | Per trial protocol | Ongoing; no results posted | NCT07104500 — VK2735 for Weight Management Phase 3 |
| VENTURE-Oral — phase 2, daily tablet (NCT06828055)Clinical trial · Phase 2 randomized, placebo-controlled trial | Adults with obesity or overweight (n=280) | Six oral dose arms; amounts not given in the registry | Oral | Once daily | Per trial protocol | Completed; no results posted on ClinicalTrials.gov | NCT06828055 — VK2735 for Weight Management Phase 2 (Venture Oral Dosing) |
Where sources disagree
- The only peer-reviewed efficacy data are from a 13-week trial. Longer-term effects at these doses come from phase 3 trials that have not reported.
- VK2735 pairs GLP-1 and GIP agonism like tirzepatide, but its milligram doses are its own trial arms and are not interchangeable with tirzepatide doses.
- The oral and injected forms use different doses; an injected dose does not translate to an oral one, or the reverse.